Dyne Therapeutics (NASDAQ:DYN) Hits New 12-Month Low – What’s Next?

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) reached a new 52-week low during trading on Thursday . The stock traded as low as $13.05 and last traded at $13.08, with a volume of 1281301 shares traded. The stock had previously closed at $13.79.

Wall Street Analyst Weigh In

A number of analysts have issued reports on DYN shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $45.00 price target on shares of Dyne Therapeutics in a report on Tuesday, January 14th. HC Wainwright restated a “buy” rating and set a $55.00 price target on shares of Dyne Therapeutics in a report on Friday, January 10th. Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Finally, Robert W. Baird assumed coverage on Dyne Therapeutics in a research report on Friday, December 13th. They issued an “outperform” rating and a $46.00 price target for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $49.91.

Dyne Therapeutics Trading Down 4.5 %

The company has a market cap of $1.34 billion, a P/E ratio of -3.70 and a beta of 1.11. The company has a 50-day simple moving average of $17.41 and a 200 day simple moving average of $28.03.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. On average, equities analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insiders Place Their Bets

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the transaction, the insider now directly owns 199,087 shares in the company, valued at approximately $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Richard William Scalzo sold 1,455 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $40,914.60. Following the sale, the senior vice president now directly owns 127,078 shares of the company’s stock, valued at approximately $3,573,433.36. The trade was a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,387 shares of company stock worth $142,789 over the last 90 days. Company insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Institutional investors have recently made changes to their positions in the business. State of New Jersey Common Pension Fund D acquired a new position in Dyne Therapeutics during the 3rd quarter valued at about $1,588,000. Jennison Associates LLC increased its holdings in shares of Dyne Therapeutics by 1.5% during the third quarter. Jennison Associates LLC now owns 1,346,952 shares of the company’s stock valued at $48,383,000 after acquiring an additional 19,730 shares in the last quarter. abrdn plc purchased a new position in shares of Dyne Therapeutics in the 4th quarter valued at approximately $608,000. RA Capital Management L.P. raised its position in shares of Dyne Therapeutics by 5.5% in the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after purchasing an additional 331,940 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Dyne Therapeutics by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company’s stock worth $66,802,000 after purchasing an additional 84,760 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.